Posted by Michael Wonder on 11 Jul 2023
Pluvicto receives positive recommendations from CADTH and INESSS for progressive PSMA positive metastatic castration-resistant prostate cancer
10 July 2023 - Health technology assessment agencies reinforce the therapeutic value of Pluvicto and need for new approaches to treat advanced prostate cancer.
Novartis Pharmaceuticals Canada is pleased to announce that the CADTH Canadian Drug Expert Committee and the Institut national d'excellence en santé et services sociaux (INESSS) have recommended Pluvicto (lutetium (177Lu) vipivotide tetraxetan injection) for public reimbursement.
